Developer of a nanosecond pulsed electric field technology designed to offer an alternative to pasteurization or complement it. The company specializes in non-thermal innovative technology of food processing involving the application of short-duration high-intensity electric fields, helping clients to solve the problems of food and beverage preservation and reduce energy consumption.
Blockchain, Food Loss, Food Waste, Food Tech, Supply Chain, Big Data, Ag Tech, Digitization, AI, Shelf Life Prediction, Quality Assessment, Fresh Produce, Dynamic Routing, UN SDG 12.3, Spectroscopy, Mobile App, and NIR Spectroscopy
Fiber Unlimited provides products, services, and full network solutions for in-door Plastic Optical Fiber (POF) networks.
Simple, cost effective thermal energy buffering for the built environment, with energy management software to optimise for sustainability and costs
Pleco Therapeutics is focused on developing innovative therapies for cancer, particularly orphan treatments for diseases with limited options. The company is currently engaged in pre-clinical development of its PlecoidTM medications, targeting Acute Myeloid Leukaemia and Small-Cell Lung Cancer, both of which are associated with poor prognoses. Pleco Therapeutics aims to enhance the effectiveness of existing chemotherapy regimens and improve patient outcomes by altering protein expression within the cancer microenvironment and alleviating the burden of toxic metals in cancer cells. Through these efforts, the company seeks to extend patient lifespans and improve their quality of life.
QuiX BV, located in Enschede, the Netherlands, specializes in the development of integrated and reconfigurable light-based quantum processors. The company focuses on quantum information processing through its proprietary TriPleX platform, which utilizes stoichiometric Si3N4 waveguides. QuiX offers plug-and-play solutions that enable stable and efficient processing of single photons, facilitating advancements in quantum computing. By providing both integrated photonic processors and customized devices, QuiX aims to contribute significantly to the evolution of quantum technologies, paving the way for a transformative approach to information processing.
Provider of autonomous drone services intended to focus on applications in the agricultural sector. The company's products offer innovative technology for the agricultural sector and its optimization, enabling clients to carry on their production in a more sustainable environment with less energy, labor, pollution, and costs, together with higher production.
Aiosyn uses artificial intelligence to develop algorithms to augment pathologist with clinical decision-making. The company develops a clinical diagnostics platform with multiple AI algorithms and connect with standard pathology workflows. Aiosyn's platform will also accelerate biopharma and diagnostics companies with developing AI-based biomarker development.
Prolira BV, based in Utrecht, the Netherlands, specializes in developing medical diagnostic devices for the early detection of delirium and acute encephalopathy. Founded in 2015 as a spin-off from the University Medical Center Utrecht, the company has created DeltaScan, an EEG-based device that includes a single-use electrode patch and a monitoring module. DeltaScan analyzes brain activity to provide healthcare professionals with critical insights for timely interventions. The device features a validated algorithm that enhances brain signal monitoring, displayed on a portable monitor. Prolira's management team leads various specialized groups focused on technical development, market introduction, and clinical evaluation, with support from an advisory board and collaborations with prominent academic medical centers across Europe. The company's innovation aims to improve patient outcomes by facilitating prompt diagnosis and treatment of brain-related conditions.
River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing. Currently pharmaceutical companies spend a billion dollar figure on the development of a new drug entity, with a 90% chance of it failing to reach the market. The most common reason for failure during this developmental stage is drug induced cardiac toxicity. To solve this issue we develop 3D cardiac tissues, resembling the working human heart, for advanced drug discovery and toxicity screening using a multidisciplinary human stem cell-based approach.
ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of an anatomically shaped polymer-based meniscus implant known as the Trammpolin. This innovative implant is designed to restore the protective function of the meniscus by acting as a spacer in the joint. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise gained from a collaborative initiative that began in 2010, which included universities, private companies, and support from the Dutch government. The company combines clinical, biomechanical, and polymer knowledge to advance the Trammpolin design and its prototype development.
Fring operates a hiring platform designed to streamline the recruitment of freelancers for businesses seeking flexible talent. The platform connects companies with a diverse range of available freelancers, including skilled designers, developers, marketers, and media experts. By providing real-time access to this talent pool, Fring enables organizations to build adaptable teams and efficiently complete project tasks. Additionally, the platform allows freelancers to discover engaging projects, fostering a social connection within the freelance community. Through its innovative approach, Fring aims to redefine how businesses and freelancers collaborate, making the recruitment process more straightforward and effective.
Developer of a coagulation technology intended to create a cyclodextrin-based anticoagulant reversal drug. The company's technology manufactures cyclodextrins and procoagulant cyclodextrins to treat excessive bleeding, hemophilia, trauma, surgery, and anti-coagulants-usage bleeding, enabling medical practitioners to provide therapy for the acute and long-term prevention and treatment of numerous types of thromboembolic disorders.
Xenikos B.V. is a biotechnology company based in Nijmegen, the Netherlands, focused on developing innovative therapies for T-cell mediated diseases. Founded in 2009, the company specializes in toxin-loaded anti-T-cell antibodies that serve as a therapeutic tool to reset the immune system. These antibodies are designed to specifically identify and eliminate adult T cells, particularly the activated ones, which is crucial for treating serious immune conditions and preventing rejection after organ transplantation. By advancing its immunotherapy medicines, Xenikos aims to enhance treatment outcomes and improve the health and well-being of patients suffering from severe immune-related disorders.
ScreenPoint Medical B.V., founded in 2014 and based in Nijmegen, the Netherlands, specializes in artificial intelligence software designed to aid radiologists in interpreting digital breast tomosynthesis (DBT) and mammography exams. The company develops advanced deep learning and image analysis technologies that enhance the accuracy and efficiency of breast cancer detection. By leveraging extensive curated digital image databases and a comprehensive understanding of mammogram image formation, ScreenPoint Medical's solutions improve diagnostic consistency and reduce unnecessary patient recalls. Their flagship product, Transpara, supports healthcare professionals in identifying breast cancer at earlier stages, ultimately contributing to more effective and less invasive treatment options.
Blockchain, Food Loss, Food Waste, Food Tech, Supply Chain, Big Data, Ag Tech, Digitization, AI, Shelf Life Prediction, Quality Assessment, Fresh Produce, Dynamic Routing, UN SDG 12.3, Spectroscopy, Mobile App, and NIR Spectroscopy
Provider of autonomous drone services intended to focus on applications in the agricultural sector. The company's products offer innovative technology for the agricultural sector and its optimization, enabling clients to carry on their production in a more sustainable environment with less energy, labor, pollution, and costs, together with higher production.
Axign is a fabless chip supplier serving the worldwide audio markets in consumer and professional audio. Its first product is a breakthrough audio controller chip, that combines benchmark performance with a low bill of materials for audio system manufacturers. The chip is specially suited for active speaker systems in streaming audio devices.
InteRNA Technologies B.V. is a biotechnology company based in Nijmegen, the Netherlands, with a research and development center in Utrecht. Founded in 2006, the company focuses on developing microRNA (miRNA)-based therapeutics aimed at treating cancer. These drugs target previously undruggable pathways, enhancing the effectiveness of existing therapies and addressing drug resistance. InteRNA employs advanced techniques such as massively parallel sequencing and proprietary bioinformatics to analyze and validate miRNA sequences. Recently, the company secured additional equity financing to further advance its lead program for melanoma treatment, reflecting its commitment to innovation in oncology.
Eurekite BV, based in Enschede, the Netherlands, specializes in the manufacture of flexible ceramic materials. Established in May 2015 as a spin-off from the University of Twente, the company focuses on the development and commercialization of its innovative technology, known as Flexiramics®. This technology emerged from the Inorganic Materials Science Group of the MESA + Institute for Nanotechnology, led by Professor Andre ten Elshof. Eurekite combines expertise in formulation chemistry, production technology, and composite development, with its disruptive materials attracting investment from prominent venture capital firms.
Pepscope BV, a biotechnology company, develops protein kinase activity profiling technologies. The company offers QuantaKinome, a solution to the pharmaceutical industry and academic researchers to improve the discovery and development of novel kinase inhibitors and other therapeutic compounds to find new applications of existing compounds and in due course to select optimal therapies for individual patients. Pepscope BV was founded in 2012 and is based in Nijmegen, the Netherlands.
NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiate scientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
GATT Technologies BV develops synthetic surgical hemostat and sealant products that control severe bleeding. The company provides products, such as GATT-Patch, a hemostatic sealing patch for general surgery; GATT-Tape, a tape for preventing intestinal anastomotic leakage; GATT-Spray, an adhesive elastic sealant for general surgery; and GATT-Powder, a hemostatic sealing powder. GATT Technologies BV was founded in 2011 and is based in Nijmegen, the Netherlands.
Make every word count The Textmetrics solutions enable organizations to create target group specific and corporate wide consistent content by using augmented assisted writing based on scientifically proven algorithms.. Textmetrics is your content quality platform.
Plasmacure, located in Eindhoven, the Netherlands, focuses on developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. This innovative approach not only targets and eliminates bacteria but also promotes cell proliferation and enhances microcirculation. By addressing these critical factors, Plasmacure's technology helps healthcare professionals reduce the risk of amputation and improve the overall quality of life for patients suffering from chronic wounds.
Plasmacure, located in Eindhoven, the Netherlands, focuses on developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. This innovative approach not only targets and eliminates bacteria but also promotes cell proliferation and enhances microcirculation. By addressing these critical factors, Plasmacure's technology helps healthcare professionals reduce the risk of amputation and improve the overall quality of life for patients suffering from chronic wounds.
MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.
SuperBuddy is a Netherlands-based delivery service specializing in on-demand grocery delivery. The company offers a platform that connects customers with personal shoppers, allowing users to order groceries from local stores based on their preferences. Customers can communicate directly with their personal shopper to specify their needs, ensuring a tailored shopping experience. SuperBuddy's service includes the delivery of groceries within a two-hour timeframe, providing convenience and efficiency for daily shopping needs.
Sound Energy BV is established to develop and commercialise new technologies to reduce fossile energy consumption. Their main focus is SoundEnergy’s breaktrough innovation in Thermo Acoustic Technology for Zero CO2 climate control of buildings. They are a modern company in sustainability, integrating environmental concern, scientific knowledge and business mentality. The environment will benefit most from technologies that are good cause as well as good investment.
Mellon Medical B.V., established in 2013 and headquartered in Nijmegen, the Netherlands, specializes in the development and marketing of innovative suturing tools designed for surgical applications. The company focuses on creating instruments that enable surgeons to perform single-handed stitching, thereby enhancing the efficiency and effectiveness of suturing tubular and layered structures during medical procedures. By providing advanced suturing solutions, Mellon Medical aims to improve patient outcomes and support medical specialists in delivering high-quality healthcare.
Make every word count The Textmetrics solutions enable organizations to create target group specific and corporate wide consistent content by using augmented assisted writing based on scientifically proven algorithms.. Textmetrics is your content quality platform.
ThermoSmart is a Dutch company that specializes in the development of a user-friendly Wi-Fi thermostat aimed at energy conservation. The thermostat operates independently from energy suppliers and boiler installers, allowing users to manage their home heating efficiently. It can be controlled via an online diary or directly from a smartphone, providing convenience and flexibility. By focusing on ease of use and energy savings, ThermoSmart offers a solution that helps consumers reduce their heating costs while maintaining comfort in their homes.
Xenikos B.V. is a biotechnology company based in Nijmegen, the Netherlands, focused on developing innovative therapies for T-cell mediated diseases. Founded in 2009, the company specializes in toxin-loaded anti-T-cell antibodies that serve as a therapeutic tool to reset the immune system. These antibodies are designed to specifically identify and eliminate adult T cells, particularly the activated ones, which is crucial for treating serious immune conditions and preventing rejection after organ transplantation. By advancing its immunotherapy medicines, Xenikos aims to enhance treatment outcomes and improve the health and well-being of patients suffering from severe immune-related disorders.